CN102186475B - 新抑制剂 - Google Patents

新抑制剂 Download PDF

Info

Publication number
CN102186475B
CN102186475B CN200980139148.0A CN200980139148A CN102186475B CN 102186475 B CN102186475 B CN 102186475B CN 200980139148 A CN200980139148 A CN 200980139148A CN 102186475 B CN102186475 B CN 102186475B
Authority
CN
China
Prior art keywords
compound
formula
benzo
inhibitor
base
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980139148.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102186475A (zh
Inventor
M·阿尔姆施泰特尔
H-U·德穆特
A·哈曼
U·海泽
T·霍夫曼
R·佐默
M·托尔曼
A·特雷姆尔
U-T·格特纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivorion Treatment Co ltd
Original Assignee
Probiodrug AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Probiodrug AG filed Critical Probiodrug AG
Publication of CN102186475A publication Critical patent/CN102186475A/zh
Application granted granted Critical
Publication of CN102186475B publication Critical patent/CN102186475B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
CN200980139148.0A 2008-09-04 2009-09-04 新抑制剂 Active CN102186475B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9411808P 2008-09-04 2008-09-04
US61/094,118 2008-09-04
PCT/EP2009/061453 WO2010026212A1 (en) 2008-09-04 2009-09-04 Novel inhibitors

Publications (2)

Publication Number Publication Date
CN102186475A CN102186475A (zh) 2011-09-14
CN102186475B true CN102186475B (zh) 2016-08-03

Family

ID=41278686

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980139148.0A Active CN102186475B (zh) 2008-09-04 2009-09-04 新抑制剂

Country Status (17)

Country Link
US (1) US8962860B2 (enExample)
EP (1) EP2344157B1 (enExample)
JP (1) JP5707327B2 (enExample)
KR (1) KR101694556B1 (enExample)
CN (1) CN102186475B (enExample)
AU (1) AU2009289238B2 (enExample)
BR (1) BRPI0918564B1 (enExample)
CA (1) CA2735795C (enExample)
DK (1) DK2344157T3 (enExample)
EA (1) EA021150B1 (enExample)
ES (1) ES2599621T3 (enExample)
IL (1) IL211018A (enExample)
MX (1) MX2011002106A (enExample)
NZ (1) NZ591531A (enExample)
SG (1) SG193828A1 (enExample)
WO (1) WO2010026212A1 (enExample)
ZA (1) ZA201100898B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5788320B2 (ja) * 2008-09-04 2015-09-30 プロビオドルグ エージー イソｑｃ阻害剤の使用
BR112012008346B1 (pt) * 2009-09-11 2021-12-21 Vivoryon Therapeutics N.V. Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica
US20110152341A1 (en) 2009-12-22 2011-06-23 Probiodrug Ag Cleavage of b-amyloid precursor protein
WO2012123563A1 (en) * 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
WO2012163773A1 (en) 2011-05-27 2012-12-06 Probiodrug Ag Radiolabelled glutaminyl cyclase inhibitors
EA029451B1 (ru) 2013-03-15 2018-03-30 Пробиодруг Аг Новые ингибиторы
JP2018501482A (ja) 2014-12-19 2018-01-18 プロビオドルグ エージー ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
CN108658869A (zh) * 2017-03-29 2018-10-16 复旦大学 具有抗肿瘤活性的化合物及其制备方法和在制药中的用途
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
RU2662559C1 (ru) * 2017-10-27 2018-07-26 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый ингибитор глутаминилциклаз и его применение для лечения заболеваний легких и дыхательных путей
RU2665633C1 (ru) * 2017-05-26 2018-09-03 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Новый ингибитор глутаминилциклаз и его применение
PL3461819T3 (pl) * 2017-09-29 2020-11-30 Probiodrug Ag Inhibitory cyklazy glutaminylowej
EP3521308B1 (en) 2018-01-31 2024-03-13 Vivoryon Therapeutics N.V. Humanized and de-immunized antibodies
PT3589632T (pt) 2018-02-23 2020-12-09 Fraunhofer Ges Forschung Novos inibidores de glutaminil ciclases bacterianas para utilização no tratamento de doenças periodontais e relacionadas
TWI715156B (zh) 2018-08-31 2021-01-01 財團法人國家衛生研究院 苯并咪唑化合物及其用於治療阿茲海默症或亨丁頓氏症之用途
AU2020284308B2 (en) * 2019-05-24 2026-02-05 Emory University Asparagine endopeptidase (AEP) inhibitors, compositions, and uses related thereto
MX2022000521A (es) * 2019-07-12 2022-06-14 Scenic Immunology B V Compuestos n-sustituidos-3,4-(5-anillo fusionado)-5-fenil-pirrolid in-2-ona como inhibidores de la enzima isoqc y/o qc.
TW202317549A (zh) * 2021-06-24 2023-05-01 香港商英科智能有限公司 用於治療疾病之β-內醯胺衍生物
CN121548576A (zh) * 2023-07-21 2026-02-17 英矽智能科技知识产权有限公司 结晶性β-内酰胺衍生物及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD293584A5 (de) * 1990-03-23 1991-09-05 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4320432A1 (de) * 1993-06-21 1994-12-22 Bayer Ag Substituierte Mono- und Bipyridylmethylderivate
NZ501166A (en) 1997-07-31 2001-12-21 Abbott Lab Reverse hydroxamate-containing compounds and their use as inhibitors of matrix metalloproteinases
US6235786B1 (en) * 1997-08-06 2001-05-22 Abbott Laboratories Reverse hydroxamate inhibitors of matrix metalloproteinases
ATE462432T1 (de) * 2003-05-05 2010-04-15 Probiodrug Ag Glutaminylcyclase-hemmer
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
WO2008028032A2 (en) 2006-09-01 2008-03-06 Allergan, Inc. Therapeutic substituted hydantoins and related compounds
JP5456479B2 (ja) 2006-11-09 2014-03-26 プロビオドルグ エージー グルタミニルシクラーゼの新規阻害剤
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
CN101519376B (zh) * 2008-02-27 2012-10-10 上海药明康德新药开发有限公司 一种芳香环双酰胺螺环类药物模板的合成方法
JP5788320B2 (ja) 2008-09-04 2015-09-30 プロビオドルグ エージー イソｑｃ阻害剤の使用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD293584A5 (de) * 1990-03-23 1991-09-05 Adw,Zi Fuer Organische Chemie,De Verfahren zur herstellung von neuen 3,5,5-trisubstituierten 1-(benzimidazol-2-yl)-imidazolidin-2,4-dionen bzw. -4-on-2-thionen
US20040006011A1 (en) * 1996-07-12 2004-01-08 Gour Barbara J. Peptidomimetic modulators of cell adhesion
WO2008034891A2 (en) * 2006-09-21 2008-03-27 Probiodrug Ag Novel genes related to glutaminyl cyclase

Also Published As

Publication number Publication date
ES2599621T3 (es) 2017-02-02
EA021150B1 (ru) 2015-04-30
JP2012502006A (ja) 2012-01-26
JP5707327B2 (ja) 2015-04-30
WO2010026212A1 (en) 2010-03-11
IL211018A0 (en) 2011-04-28
CN102186475A (zh) 2011-09-14
IL211018A (en) 2015-11-30
US20100119475A1 (en) 2010-05-13
AU2009289238A1 (en) 2010-03-11
NZ591531A (en) 2012-03-30
SG193828A1 (en) 2013-10-30
BRPI0918564A2 (pt) 2015-12-01
KR20110074975A (ko) 2011-07-05
CA2735795A1 (en) 2010-03-11
US8962860B2 (en) 2015-02-24
ZA201100898B (en) 2012-02-29
CA2735795C (en) 2018-02-20
EA201100424A1 (ru) 2011-10-31
MX2011002106A (es) 2011-04-07
AU2009289238B2 (en) 2014-09-04
BRPI0918564B1 (pt) 2023-11-28
DK2344157T3 (en) 2016-09-05
KR101694556B1 (ko) 2017-01-09
EP2344157B1 (en) 2016-05-25
EP2344157A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
CN102186475B (zh) 新抑制剂
JP5798157B2 (ja) 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
EP2142513B1 (en) Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
CN102791704B (zh) 谷氨酰胺酰环化酶(qc, ec 2.3.2.5)的杂环抑制剂
JP6026284B2 (ja) グルタミニルシクラーゼの阻害剤
US8227498B2 (en) Inhibitors of glutaminyl cyclase
EP2142515B1 (en) Nitrovinyl-diamine derivatives as glutaminyl cyclase inhibitors
JP2010509285A (ja) グルタミニルシクラーゼの新規阻害剤
JP2010524896A (ja) グルタミニルシクラーゼ阻害剤としてのアミノピリジン誘導体
JP2010524897A (ja) グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
HK1161540A (en) Novel inhibitors
HK1161540B (en) Novel inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1161540

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1161540

Country of ref document: HK

CP01 Change in the name or title of a patent holder

Address after: Halle

Patentee after: Vivorion treatment Co.,Ltd.

Address before: Halle

Patentee before: PROBIODRUG AG

CP01 Change in the name or title of a patent holder